Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Down – Here’s Why

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY)’s share price gapped down before the market opened on Monday . The stock had previously closed at $24.22, but opened at $22.55. Chugai Pharmaceutical shares last traded at $23.5419, with a volume of 1,700 shares changing hands.

Chugai Pharmaceutical Stock Performance

The company’s 50-day moving average price is $23.04 and its 200 day moving average price is $24.27. The stock has a market capitalization of $77.69 billion, a PE ratio of 29.51 and a beta of 0.64.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last posted its quarterly earnings data on Friday, October 24th. The company reported $0.23 earnings per share (EPS) for the quarter. The business had revenue of $2.26 billion during the quarter. Chugai Pharmaceutical had a return on equity of 20.63% and a net margin of 32.74%. Analysts expect that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 earnings per share for the current year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.